Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Gilead, Sanofi Ink Academic R&D Pacts

by Rick Mullin
April 4, 2011 | A version of this story appeared in Volume 89, Issue 14

Gilead Sciences and Yale School of Medicine have formed a multiyear collaboration to discover novel cancer therapies. Research will focus on the genetic basis and underlying mechanisms of cancer. Gilead will fund the initial four-year research period with up to $40 million and could pay as much as $100 million over 10 years if the project is renewed. Meanwhile, Sanofi-Aventis has formed a collaboration with Columbia University Medical Center focused on diabetes treatments. The three-year project will investigate the role of osteocalcin, an osteoblast-secreted peptide, in diabetes management. Sanofi will fund research at Columbia and will have an option to license existing patents and results from ongoing research.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.